Efficacy and Safety Outcomes by BMI Category Over 48 Weeks in Phase 3/3b Cabotegravir and Rilpivirine Long-Acting Trials

<u>Emilie Elliot</u>¹, Joseph W. Polli¹, Parul Patel¹, Louise Garside², Richard Grove³, Vince Barnett⁴, Jeremy Roberts⁵, Herta Crauwels⁶, Susan L. Ford⁴, Eileen Birmingham⁷, Ronald D'Amico¹, Bryan Baugh⁸, Matt Bosse¹

¹ViiV Healthcare, Research Triangle Park, NC, United States; ²GlaxoSmithKline, London, United Kingdom; ³GlaxoSmithKline, Uxbridge, United Kingdom; ⁴GlaxoSmithKline, Research Triangle Park, NC, United States; ⁵GlaxoSmithKline, Mississauga, ON, Canada; ⁶Janssen Research & Development, Beerse, Belgium; ⁷Janssen Research & Development, Raritan, NJ, United States; ⁸Janssen Research & Development, Titusville, NJ, United States

18th European AIDS Conference; October 27–30, 2021; Virtual and London, United Kingdom

Disclosure

• Emilie Elliot is an employee of ViiV Healthcare and stockholder of GlaxoSmithKline

2

Introduction

- Cabotegravir (CAB) + rilpivirine (RPV) is the first complete long-acting (LA) regimen recommended by the US DHHS and IAS–USA treatment guidelines for the maintenance of HIV-1 virologic suppression^{1,2}
- CAB + RPV LA has demonstrated favorable efficacy and safety with a low 1% rate of confirmed virologic failure (CVF) when dosed monthly or every 2 months through 96 weeks across diverse subgroups^{3–8}
- The global prevalence of overweight and obesity in people living with HIV has been rising and is associated with many comorbidities⁹
- Efficacy, safety, and pharmacokinetics (PK) of CAB + RPV LA are presented through Week 48 among Phase 3/3b trial participants, stratified by baseline body mass index (BMI) category

US DHHS, United States Department of Health and Human Services; IAS–USA, International Antiviral Society–United States of America.

^{1.} US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2021. Available from: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/15/virologic-failure. Accessed August 2021. 2. Saag MS, et al. *JAMA*. 2020;324(16):1651–1669. 3. Swindells S, et al. *N Engl J Med*. 2020;382(12):1112–1123. 4. Swindells S, et al. *AIDS*. Accepted 2021. 5. Orkin C, et al. *N Engl J Med*. 2020;382(12):1124–1135. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/15/virologic-failure. Accessed August 2021. 2. Saag MS, et al. *JAMA*. 2020;324(16):1651–1669. 3. Swindells S, et al. *N Engl J Med*. 2020;382(12):1124–1135. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/15/virologic-failure. Accessed August 2021. 2. Saag MS, et al. *JAMA*. 2020;324(16):1651–1669. 3. Swindells S, et al. *N Engl J Med*. 2020;382(12):1124–1135. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/15/virologic-failure. Accessed August 2021. 2. Saag MS, et al. *JAMA*. 2020;324(16):1651–1669. 3. Swindells S, et al. *N Engl J Med*. 2020;382(12):1124–1135. https://aidsinfo.nih.gov/guidelines/html/1/adult-adult-adolescent-arv/15/virologic-failure. Accessed August 2021. 9. Koethe JR, et al. *AIDS Res Hum Retroviruses*. 2016;32(1):50–58.

Methods

- Data were pooled for participants without prior exposure to CAB + RPV receiving CAB + RPV LA every 8 weeks (Q8W) or every 4 weeks (Q4W) in the ATLAS, FLAIR, and ATLAS-2M studies
- Participants were categorized by dosing regimen (Q8W vs. Q4W) and BMI category (lower, <30 kg/m²; higher, ≥30 kg/m²)

Endpoints Evaluated Through Week 48 by BMI Category

- The proportion of participants with plasma HIV-1 RNA ≥50 and <50 copies/mL
- The incidence of CVF (two consecutive HIV-1 RNA ≥200 copies/mL)
- Safety, including injection site reaction (ISR) adverse events (AEs)
- CAB and RPV plasma trough concentrations through Week 48

BMI, body mass index; CAB, cabotegravir; CVF, confirmed virologic failure; LA, long-acting; RPV, rilpivirine.

Baseline Characteristics

	Pooled CAB + R	Pooled CAB + RPV LA participants across ATLAS, FLAIR, and ATLAS-2M				
	BMI <30 kg/m² (n=1032)		BMI ≥30 kg/m² (n=213)			
ITT-E population	Q8W (n=268)	Q4W (n=764)	Q8W (n=59)	Q4W (n=154)		
Age, median (range) years	41 (20–83)	38 (19–68)	43 (32–71)	41 (23–74)		
≥50 years, n (%)	73 (27)	148 (19)	16 (27)	37 (24)		
Female (sex at birth), n (%)	48 (18)	172 (23)	25 (42)	65 (42)		
Race, n (%)						
White	201 (75)	591 (77)	37 (63)	95 (62)		
Black or African American	37 (14)	103 (13)	20 (34)	51 (33)		
Asian	17 (6)	44 (6)	0	2 (1)		
Other	13 (5)	26 (3)	2 (3)	6 (4)		
Hispanic or Latinx ethnicity, n (%)	43 (16)	89 (12)	11 (19)	16 (10)		
Weight, median (range) kg	74.0 (49.0–109.2)	73.2 (41.2–108.4)	98.0 (76.0–136.9)	99.9 (70.9–139.4)		
BMI, median (range) kg/m ²	24.4 (17.8–30.0)	24.0 (15.3–29.9)	32.5 (30.1–46.0)	33.2 (30.0–54.0)		
30–<40, n (%)	N/A	N/A	49 (83)	139 (90)		
≥40, n (%)	N/A	N/A	10 (17)	15 (10)		

 Among 1245 participants randomized to receive CAB + RPV LA, 213 (17%) had a BMI ≥30 kg/m² at baseline

BMI, body mass index; CAB, cabotegravir; CVF, confirmed virologic failure; ITT-E, intention-to-treat exposed; LA, long-acting; Q4W, every 4 weeks; Q8W, every 8 weeks; RPV, rilpivirine.

Viral Suppression Was High and Comparable Across BMI Categories

	Pooled CAB + I	RPV LA participants a	cross ATLAS, FLAIR	ross ATLAS, FLAIR, and ATLAS-2M	
	BMI <30 kg/m² (n=1032)		BMI ≥30 kg/m² (n=213)		
Parameter, n (%)	Q8W (n=268)	Q4W (n=764)	Q8W (n=59)	Q4W (n=154)	
HIV-1 RNA <50 copies/mL	252 (94)	708 (92.7)	54 (91.5)	142 (92.2)	
HIV-1 RNA ≥50 copies/mL	1 (0.4)	9 (1.2)	4 (6.8)	7 (4.5)	
Data in window not below threshold	1 (0.4)	1 (0.1)	0	4 (2.6)	
Discontinued for lack of efficacy	0	6 (0.8)	4 (6.8)	3 (1.9)	
Discontinued for other reason while not below threshold	0	2 (0.3)	0	0	
No virologic data in Week 48 window	15 (5.6)	47 (6.2)	1 (1.7)	5 (3.2)	
Discontinued due to AE or death	6 (2.2)	29 (3.8)	0	1 (0.6)	
Discontinued for other reasons	9 (3.4)	18 (2.4)	1 (1.7)	4 (2.6)	

- At Week 48, across both dosing regimens, 93–94% of participants in the lower BMI group had HIV-1 RNA <50 copies/mL vs. 92% in the higher BMI group
- Overall, 10 vs. 11 participants had HIV-1 RNA ≥50 copies/mL in the lower and higher BMI groups, respectively

AE, adverse event; BMI, body mass index; CAB, cabotegravir; LA, long-acting; Q4W, every 4 weeks; Q8W, every 8 weeks; RPV, rilpivirine.

No Participant With BMI ≥30 kg/m² As the Only Baseline Factor Met the CVF Criterion Through Week 48

	Pooled CAB + RPV LA participants across ATLAS, FLAIR, and ATLAS-2M			
	BMI <30 kg/m² (n=1032)	BMI ≥30 kg/m² (n=213)		
CVF through Week 48, n	5*	8†		
No other baseline factors, n	3	O [‡]		
At least one other baseline factor, n	2	8		
RPV resistance-associated mutations alone	0	3		
HIV-1 subtype A6/A1 alone	1	4		
Both	1	1		

- Amongst 153[§] participants with BMI ≥30 kg/m² as the only baseline factor, none met the CVF criterion
- CVF events were uncommon across all three Phase 3/3b studies through 48 weeks of CAB + RPV LA (n=13/1245, 1%)^{II}

*Q8W, n=4: Q4W, n=4. †Q8W, n=4; Q4W, n=4. ‡BMI ≥30 kg/m² was the only baseline risk factor. [§]Of the 213 participants with a BMI ≥30 kg/m², 185 had data available for HIV-1 subtype and RPV resistance-associated mutations; among the 28 participants who were missing data for one or both of the other baseline factors, none met the CVF criterion. ^IOne participant had oral CAB + RPV dosing interrupted due to a false-positive pregnancy test and, upon reinitiation of oral therapy, had suspected virologic failure that was confirmed. <u>BMI, body mass index;</u> CAB, cabotegravir; CVF, confirmed virologic failure; LA, long-acting; Q4W, every 4 weeks; Q8W, every 8 weeks; RPV, rilpivirine.


Safety Summary (Excluding ISRs)

	Pooled CAB + R	Pooled CAB + RPV LA participants across ATLAS, FLAIR, and ATLAS-2M			
	BMI <30	BMI <30 kg/m²		BMI ≥30 kg/m²	
	Q8W	Q4W	Q8W	Q4W	
Parameter, n (%)	(n=268)	(n=764)	(n=59)	(n=154)	
Any AE	211 (79)	656 (86)	41 (69)	127 (82)	
Any Grade ≥3 AE	14 (5)	55 (7)	1 (2)	8 (5)	
Any drug-related AE	66 (25)	218 (29)	8 (14)	43 (28)	
Any Grade ≥3 drug-related AE	2 (<1)	12 (2)	0	0	
AE leading to withdrawal	6 (2)	26 (3)	0	1 (<1)	
Any serious AE*	13 (5)	30 (4)	2 (3)	5 (3)	
Drug related	0	2 (<1)	0	0	

 Drug-related Grade ≥3 AEs (excluding ISRs) were uncommon, occurring in <1% of participants across both BMI categories and dosing regimens

*None were fatal. <u>AE, adverse</u> event; BMI, body mass index; CAB, cabotegravir; ISR, injection site reaction; LA, long-acting; Q4W, every 4 weeks; Q8W, every 8 weeks; RPV, rilpivirine.


Most ISRs Were Mild or Moderate in Severity



- ISR incidence decreased over time regardless of BMI group or dosing regimen, with a numerical trend toward fewer ISRs in the higher BMI group
- The majority of ISRs were short-lived (median, 3 days), with injection site pain the most commonly reported (22% of all injections), regardless of BMI or dosing regimen

*AE grade is the maximum grade reported by the participant at each visit. Few ISRs were classified as Grade 3 (~1% of ISR events), consistent across both BMI categories and regimens. There were no Grade 4 or 5 ISR events. <u>AE, adverse</u> event; BMI, body mass index; CAB, cabotegravir; ISR, injection site reaction; LA, long-acting; Q4W, every 4 weeks; Q8W, every 8 weeks; RPV, rilpivirine; W, week.


CAB and RPV Troughs Remained Above Respective PA-IC₉₀ Targets Regardless of Baseline BMI Category



- Median CAB troughs tended to be lower initially in participants with baseline BMI ≥30 kg/m², but this trend disappeared by Week 48
- RPV concentrations were unaffected by BMI category, consistent with previous findings²

*Participant numbers for CAB administration are shown. RPV participant numbers were identical with the following exceptions: Q8W, <30 kg/m²: Week 16, n=259; Q8W, \geq 30 kg/m²: Week 4, n=58; Week 8, n= 58; Q4W, <30 kg/m²: Week 8, n=743; Week 16, n= 730; Week 24, n=718; Week 32, n=715; Week 44, n=450; Week 48, n=691; Q4W, \geq 30 kg/m²: Week 4, n=152; Week 12, n=101; Week 24, n=147; Week 40, n=143; Week 48, n=144. BMI, body mass index; CAB, cabotegravir; PA-IC₉₀, protein-adjusted 90% inhibitory concentration; Q4W, every 4 weeks; Q8W, every 8 weeks. <u>1. Cutrell A</u>G, et al. *AIDS*. 2021;35(9):1333–1342. 2. Han K, et al. 22nd International AIDS Conference; Amsterdam, The Netherlands; July 23–27, 2018; poster WEPDB0205.

Longer Needle Lengths Were Associated With Higher CAB Troughs in the BMI ≥30 kg/m² Group Early in Treatment



• Use of longer 2-inch needles resulted in higher median CAB trough concentrations for participants with BMI ≥30 kg/m²

 Longer 2-inch needles are recommended to accommodate individual body habitus and in participants with BMI ≥30 kg/m² to ensure appropriate administration into gluteal muscle[†]

^{*}Data beyond Week 40 were not available at time of analysis.

[†]The majority (78%, n=3889/4970) of injections in participants with BMI ≥30 kg/m² were administered with needles <1.6 inches in length vs. the recommended longer 2-inch needle due to issues with procurement. BMI, body mass index; CAB, cabotegravir; PA-IC_{a0}, protein-adjusted 90% inhibitory concentration; Q4W, every 4 weeks; Q8W, every 8 weeks.

Conclusions

- CAB + RPV LA Q4W and Q8W maintained high virologic suppression rates through Week 48 in Phase 3/3b trials, regardless of baseline BMI category
- Injections were well tolerated regardless of BMI category, rarely leading to study withdrawal; most ISRs were classified as mild to moderate in severity and decreased in incidence over time
- No participant with BMI ≥30 kg/m² as the only baseline risk factor met the CVF criterion through Week 48
- These data support the use of CAB + RPV LA dosed monthly or every 2 months as a complete regimen for the maintenance of HIV-1 virologic suppression in adults regardless of BMI category

BMI, body mass index; CAB, cabotegravir; CVF, confirmed virologic failure; ISR, injection site reaction; LA, long-acting; Q4W, every 4 weeks; Q8W, every 8 weeks; RPV, rilpivirine.

Acknowledgments

 We thank everyone who has contributed to the success of the FLAIR, ATLAS, and ATLAS-2M studies: all study participants and their families; the clinical investigators and their staff; and the ViiV Healthcare, GlaxoSmithKline, and Janssen study team members This content was acquired following an unsolicited medical information enquiry by a healthcare professional.

Always consult the product information for your country before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their licence.

In some cases, the scientific information requested and downloaded may relate to the use of our medicine(s) outside of their licence.

